Correlation Between Cipher Pharmaceuticals and Canntab Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cipher Pharmaceuticals and Canntab Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cipher Pharmaceuticals and Canntab Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cipher Pharmaceuticals and Canntab Therapeutics Limited, you can compare the effects of market volatilities on Cipher Pharmaceuticals and Canntab Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cipher Pharmaceuticals with a short position of Canntab Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cipher Pharmaceuticals and Canntab Therapeutics.

Diversification Opportunities for Cipher Pharmaceuticals and Canntab Therapeutics

-0.15
  Correlation Coefficient

Good diversification

The 3 months correlation between Cipher and Canntab is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Cipher Pharmaceuticals and Canntab Therapeutics Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Canntab Therapeutics and Cipher Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cipher Pharmaceuticals are associated (or correlated) with Canntab Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Canntab Therapeutics has no effect on the direction of Cipher Pharmaceuticals i.e., Cipher Pharmaceuticals and Canntab Therapeutics go up and down completely randomly.

Pair Corralation between Cipher Pharmaceuticals and Canntab Therapeutics

Assuming the 90 days horizon Cipher Pharmaceuticals is expected to generate 1.92 times less return on investment than Canntab Therapeutics. But when comparing it to its historical volatility, Cipher Pharmaceuticals is 1.87 times less risky than Canntab Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Canntab Therapeutics Limited is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  1.60  in Canntab Therapeutics Limited on August 29, 2024 and sell it today you would lose (1.59) from holding Canntab Therapeutics Limited or give up 99.37% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy8.69%
ValuesDaily Returns

Cipher Pharmaceuticals  vs.  Canntab Therapeutics Limited

 Performance 
       Timeline  
Cipher Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cipher Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Cipher Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders.
Canntab Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Canntab Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental drivers remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Cipher Pharmaceuticals and Canntab Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cipher Pharmaceuticals and Canntab Therapeutics

The main advantage of trading using opposite Cipher Pharmaceuticals and Canntab Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cipher Pharmaceuticals position performs unexpectedly, Canntab Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Canntab Therapeutics will offset losses from the drop in Canntab Therapeutics' long position.
The idea behind Cipher Pharmaceuticals and Canntab Therapeutics Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device